Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 2
2017 4
2018 3
2019 5
2020 3
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

20 results
Results by year
Filters applied: . Clear all
Page 1
Cross-talk among writers, readers, and erasers of m6A regulates cancer growth and progression.
Panneerdoss S, Eedunuri VK, Yadav P, Timilsina S, Rajamanickam S, Viswanadhapalli S, Abdelfattah N, Onyeagucha BC, Cui X, Lai Z, Mohammad TA, Gupta YK, Huang TH, Huang Y, Chen Y, Rao MK. Panneerdoss S, et al. Among authors: viswanadhapalli s. Sci Adv. 2018 Oct 3;4(10):eaar8263. doi: 10.1126/sciadv.aar8263. eCollection 2018 Oct. Sci Adv. 2018. PMID: 30306128 Free PMC article.
EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer.
Viswanadhapalli S, Luo Y, Sareddy GR, Santhamma B, Zhou M, Li M, Ma S, Sonavane R, Pratap UP, Altwegg KA, Li X, Chang A, Chávez-Riveros A, Dileep KV, Zhang KYJ, Pan X, Murali R, Bajda M, Raj GV, Brenner AJ, Manthati V, Rao MK, Tekmal RR, Nair HB, Nickisch KJ, Vadlamudi RK. Viswanadhapalli S, et al. Mol Cancer Ther. 2019 Aug;18(8):1341-1354. doi: 10.1158/1535-7163.MCT-18-1258. Epub 2019 May 29. Mol Cancer Ther. 2019. PMID: 31142661 Free PMC article.
Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers.
Viswanadhapalli S, Ma S, Sareddy GR, Lee TK, Li M, Gilbreath C, Liu X, Luo Y, Pratap UP, Zhou M, Blatt EB, Kassees K, Arteaga C, Alluri P, Rao M, Weintraub ST, Tekmal RR, Ahn JM, Raj GV, Vadlamudi RK. Viswanadhapalli S, et al. Breast Cancer Res. 2019 Dec 26;21(1):150. doi: 10.1186/s13058-019-1227-8. Breast Cancer Res. 2019. PMID: 31878959 Free PMC article.
PELP1 promotes glioblastoma progression by enhancing Wnt/β-catenin signaling.
Sareddy GR, Pratap UP, Viswanadhapalli S, Venkata PP, Nair BC, Krishnan SR, Zheng S, Gilbert AR, Brenner AJ, Brann DW, Vadlamudi RK. Sareddy GR, et al. Among authors: viswanadhapalli s. Neurooncol Adv. 2019 May-Dec;1(1):vdz042. doi: 10.1093/noajnl/vdz042. Epub 2019 Nov 5. Neurooncol Adv. 2019. PMID: 32309805 Free PMC article.
EC330, a small-molecule compound, is a potential novel inhibitor of LIF signaling.
Yue X, Wu F, Wang J, Kim K, Santhamma B, Dileep KV, Zhang KYJ, Viswanadhapalli S, Vadlamudi RK, Ahmed G, Feng Z, Nickisch K, Hu W. Yue X, et al. Among authors: viswanadhapalli s. J Mol Cell Biol. 2020 Jul 3;12(6):477-480. doi: 10.1093/jmcb/mjaa008. J Mol Cell Biol. 2020. PMID: 32221559 Free PMC article. No abstract available.
KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer.
Zhou M, Venkata PP, Viswanadhapalli S, Palacios B, Alejo S, Chen Y, He Y, Pratap UP, Liu J, Zou Y, Lai Z, Suzuki T, Brenner AJ, Tekmal RR, Vadlamudi RK, Sareddy GR. Zhou M, et al. Among authors: viswanadhapalli s. Breast Cancer Res Treat. 2021 Jan;185(2):343-357. doi: 10.1007/s10549-020-05963-1. Epub 2020 Oct 14. Breast Cancer Res Treat. 2021. PMID: 33057995
Nox4 is a Target for Tuberin Deficiency Syndrome.
Shi Q, Viswanadhapalli S, Friedrichs WE, Velagapudi C, Szyndralewiez C, Bansal S, Bhat MA, Choudhury GG, Abboud HE. Shi Q, et al. Among authors: viswanadhapalli s. Sci Rep. 2018 Feb 28;8(1):3781. doi: 10.1038/s41598-018-21838-4. Sci Rep. 2018. PMID: 29491408 Free PMC article.
20 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page